Mobile Health Tool for Asthma
(AIM2ACT Trial)

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen bySreekala Prabhakaran, M.D.

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Florida

No Placebo Group

Trial Summary

What is the purpose of this trial?The aim is to test the efficacy of AIM2ACT and long-term maintenance of treatment effects in a fully-powered randomized controlled trial with 160 early adolescents with poorly controlled persistent asthma, ages 12-15 years, and a caregiver

Eligibility Criteria

This trial is for early adolescents aged 12-15 with poorly controlled asthma and their caregivers (18-70 years old). Participants must speak English, live with the caregiver, and have experienced recent frequent asthma symptoms or have a history of severe asthma events. Adolescents should be on inhaled corticosteroids and diagnosed with asthma.

Inclusion Criteria

I have been using an inhaled corticosteroid for at least 4 weeks.

My caregiver is between 18 and 70 years old.

I have had frequent asthma symptoms or needed emergency care for asthma recently.

+4 more

Exclusion Criteria

Your family is currently getting extra help for managing asthma.

I cannot do the study tasks by myself.

Participant Groups

The AIM2ACT study tests a mobile health tool designed to help young teens manage their asthma against an attention control condition. It's a randomized controlled trial involving 160 pairs of adolescents and caregivers to see if the tool can improve long-term asthma control.

2Treatment groups

Experimental Treatment

Active Control

Group I: AIM2ACTExperimental Treatment1 Intervention

AIM2ACT is the experimental arm for the trial. AIM2ACT is a dyadic mHealth intervention designed to sustain caregiver involvement and monitoring as well as guide dyads through collaborative asthma management.

Group II: mHealth Attention Control ConditionActive Control1 Intervention

The mHealth attention control condition is the active comparator arm in the trial that accounts for staff attention and novelty of technology based asthma management intervention.